Difei Yang, Ph.D., is Managing Director of Equity Research at Mizuho Americas, Research Division. Dr. Yang has been covering the biotech and pharma sector for nearly a decade, most recently as Managing Director at Aegis Capital. She also worked in senior equity analyst roles at Brean Capital, R.F. Lafferty, WallachBeth Capital and Auriga Global Investors. In addition, she has held senior science, program management and business development roles within the pharmaceutical industry and has authored many granted U.S. patents and peer-reviewed scientific publications. She holds a Ph.D. in chemistry from UCLA, as well as an MBA from Georgia State University and a B.S. degree in physics from Peking University, China.
Raghuram Selvaraju, Ph.D., MBA, is Managing Director of Equity Research and Senior Healthcare Analyst at H.C. Wainwright & Co, LLC, Research Division. Dr. Selvaraju has served in these roles since August 2015. He focuses on health care research at the firm. He was previously employed at Rodman & Renshaw Research, which he had rejoined. Earlier, Dr. Selvaraju started his sellside Research Analyst career at Rodman & Renshaw in 2005. Prior to rejoining Rodman, he served as a Managing Director and Senior Healthcare Analyst at MLV & Co LLC, Research Division. Dr. Selvaraju was employed at MLV between November 2014 and August 2015. He covered the biotechnology, specialty pharmaceuticals and diagnostics space within the health care sector at the firm. Prior to this, Dr. Selvaraju served as Managing Director, Head of Healthcare Equity Research and Senior Analyst at Aegis Capital Corporation between March 2012 and November 2014. Before that, he served as a Senior Vice President in Equity Research and Senior Biotechnology Analyst at Morgan Joseph TriArtisan LLC, Research Division from May 2011 to March 2012. From mid-2010 to March 2011, Dr. Selvaraju served as a Senior Equity Research Analyst covering the biotechnology and pharmaceuticals sectors at NOBLE Capital Markets, Inc., Research Division. From 2009 to 2010, he served as the Senior Vice President and Head of Healthcare Equity Research at Hapoalim Securities USA, Inc., Research Division, covering biotechnology, specialty pharmaceuticals, molecular analytics and diagnostics. Prior to entering the equity research field on Wall Street, Dr. Selvaraju started his career at the Serono Pharmaceutical Research Institute in 2000. He served as a technician and pharmaceutical researcher at the firm until 2004. Dr. Selvaraju designed models and user interfaces for analysis of gene expression data from quantitative real-time RT-PCR; led multidisciplinary teams developing animal models to identify novel therapeutic products; and discovered the first novel protein candidate. He has nearly 15 years’ worth of experience in health care equity research. Dr. Selvaraju has served as Chairman of THERAMetrics Holding AG, now known as Relief Therapeutics Holding AG, since June 2, 2016. He has nearly two decades of total experience in the biotechnology and pharmaceutical sectors. Dr. Selvaraju is widely quoted in national publications such as Barron’s and The Wall Street Journal, as well as health care industry publications such as The Pink Sheet, BioWorld Today and BioCentury, and has appeared numerous times on Bloomberg, CNBC, Business News Network and BTV to comment on drug development trends, health care reform policy, and pharma and biotech merger and acquisition. He has published articles in leading peer-reviewed journals, presented research at various international scientific conferences and is a co-inventor on several drug patents. Dr. Selvaraju has published sector reports on Alzheimer’s disease, multiple sclerosis, stroke, orphan neurological disorders and some of the most extensive Wall Street research on United States health care reform policy. He has been ranked on StarMine for earnings accuracy since 2010 and also by The Wall Street Journal’s Best on the Street survey on the basis of portfolio return performance in 2006. Dr. Selvaraju has been ranked by StarMine for earnings accuracy as well as The Wall Street Journal’s Best on the Street survey for his stock-picking performance. While at Serono Pharmaceutical Research Institute, he became the youngest-ever recipient of the Serono Pharmaceutical Research Institute’s Inventorship Award for exceptional innovation and creativity in 2003. Dr. Selvaraju graduated in 1999 with a Bachelor of Science in biological sciences and technical writing from Carnegie Mellon University, a Ph.D. in cellular immunology and molecular neuroscience in 2004, a Master of Science in molecular biology from the University of Geneva in Switzerland in 2001 on the basis of his drug development research and an MBA from Cornell University’s accelerated one-year program for scientists and engineers in 2005.
Michael Ciarmoli joined SunTrust Robinson Humphrey in late 2016 as Director to cover the aerospace and defense sector. He has more than nine years of experience as a senior publishing analyst. Most recently, he was an Executive Director at KeyBanc for six years, with prior experience at Boenning & Scattergood and Emerging Growth Equities. Mr. Ciarmoli spent the previous five years as a consultant and product specialist at Accenture and Wilmington Trust Company respectively. He received his MBA from Drexel University and completed his undergraduate degree in finance at Villanova University.
Brooks O’Neil is a Senior Research Analyst at Lake Street Capital Markets, LLC. Mr. O’Neil has expertise in high-potential, but underappreciated health care service and device companies. He has spent nearly 30 years in equity capital markets and investment banking focused primarily on emerging growth companies. Prior to joining Lake Street, Mr. O’Neil was at Piper Jaffray in Minneapolis for 15 years in Institutional equity research, sales, and investment banking, and spent 10 years as a health care research analyst at Dougherty & Co. Mr. O’Neil was recognized by Thomson Reuters Starmine tracking as the No. 1 stock picker out of 65 analysts covering the health services sector twice while at Dougherty. Prior to his career in finance, he worked in sales and marketing for Procter & Gamble, General Mills, and American Express. Mr. O’Neil earned a bachelor of arts degree in English from the University of Connecticut and an MBA from The Tuck School at Dartmouth College.
Brian Marckx, CFA, is Director of Research and Senior MedTech Analyst at Zacks Investment Research. Prior to joining Zacks, Mr. Marckx worked as a high yield bond analyst on Wachovia Securities’ institutional trading desks where he specialized in the health care and industrials industries. Prior to that, he was an analyst in corporate finance at First Union National Bank. Mr. Marckx has covered the medical device, pharmaceutical and biotechnology industries since joining Zacks in 2007. Brian Marckx has been quoted in numerous publications, including The Wall Street Journal, Barron’s, Bloomberg Businessweek and Kiplinger. His work has also been cited in various market studies and working papers, including those from Massachusetts Institute of Technology, Deloitte & Touche and Pharmaceutical Manufacturing. Mr. Marckx graduated with a B.S. in finance from St. John Fisher College and received his MBA from Wake Forest University. Brian Marckx is a holder of the Chartered Financial Analyst — CFA — designation.
Margaret Kaczor is Senior Equity Research Analyst of William Blair & Company, L.L.C. Ms. Kaczor joined William Blair in June 2010 and covers medical technology companies, with particular interest in diabetes, cardiovascular disease, kidney disease, respiratory therapy and aesthetics. Ms. Kaczor was named the number-two stock-picker in the 2015 StarMine Analyst Awards for her coverage of health care equipment and supplies. In 2016, Institutional Investor named Ms. Kaczor a “Rising Star of Wall Street Research.” She earned B.S. degrees in both accounting and finance from the University of Illinois.
Alan Phillips is Publisher and Founder of DRONELIFE.com, and Analyst and Adviser to the Drone Economy Strategy ETF at Exchange Traded Managers Group LLC. Mr. Phillips is a serial entrepreneur, active angel investor and a drone enthusiast. He co-founded DRONELIFE.com to address the emerging commercial market for drones and drone technology. Prior to DRONELIFE.com, Mr. Phillips co-founded Where.com, ThinkingScreen Media, Nurse.com and Homeplete.com. At Ziff-Davis Publishing, Mr. Phillips was EVP of ZDNet, where he helped build and sell the technology publishing powerhouse.
Harsh Kumar is a Managing Director and Senior Research Analyst at Piper Jaffray & Co. covering the semiconductor sector. Harsh joined Piper Jaffray in 2017; he has covered the semiconductor industry since the mid-1990s. Kumar has primarily focused on communication, analog and compound semiconductor companies within the sector. He was recognized as a Wall Street Journal Best on the Street analyst in 2008 and 2010 in the semiconductor category. Kumar graduated with a Bachelor of Science degree in engineering from the University of Poona in India and a Master of Business Administration degree from the University of Texas, Arlington.
Hans C. Mosesmann is Managing Director of Rosenblatt Securities Inc. Prior to joining Rosenblatt Securities, where Mr. Mosesmann is a long-standing analyst, he was an electrical engineer who spent a decade working at the chipmakers Texas Instruments and Advanced Micro Devices before moving to Wall Street in 1996. Mr. Mosesmann spent a decade at Raymond James & Associates, Inc. covering the semiconductor industry. Prior to that, he worked as an equity analyst for several boutiques, including Needham & Company, LLC, Volpe Brown Whelan & Co. and Soundview Securities, as well as Prudential Securities. Mr. Mosesmann holds a Bachelor of Science in electrical engineering from the University of Florida and an MBA in finance from Loyola University of Maryland.
Meyer Shields is Managing Director at Keefe, Bruyette & Woods (KBW). He joined KBW in 2013 and covers property and casualty insurance. Previously, he was a Director at Stifel, covering property and casualty insurance. Earlier, Mr. Meyer was an Associate Analyst at Legg Mason and J.P. Morgan. Mr. Shields’ industry experience includes eight years of increasing responsibility within Zurich Financial Services’ actuarial department. Mr. Meyer received a B.Sc. degree from the University of Toronto in actuarial science. He is also a Fellow of the Casualty Actuarial Society.
